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ABSTRACT: To address limitations in the production of DNA aptamers against small
molecules, we introduce a DNA-based capture-SELEX (systematic evolution of ligands by
exponential enrichment) protocol with long and continuous randomized library for more
ﬂexibility, coupled with in-stream direct-speciﬁcity monitoring via SPR and high throughput
sequencing (HTS). Applying this capture-SELEX on tobramycin shows that target-speciﬁcity
arises at cycle number 8, which is conﬁrmed by sequence convergence in HTS analysis.
Interestingly, HTS also shows that the most enriched sequences are already visible after only
two capture-SELEX cycles. The best aptamers displayed KD of approximately 200 nM,
similar to RNA and DNA-based aptamers previously selected for tobramycin. The lowest
concentration of tobramycin detected on label-free SPR experiments with the selected
aptamers is 20-fold smaller than the clinical range limit, demonstrating suitability for small-
drug biosensing.
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■ INTRODUCTION
Aptamers are single stranded oligonucleotides able to bind non-
nucleotidic target molecules with high aﬃnity. Aptamers are
obtained through in vitro evolution-like protocols called SELEX
(systematic evolution of ligands by exponential enrichment),
and they were ﬁrst selected more than 20 years ago on RNA1,2
or DNA3 backbones. When compared with antibodies,
aptamers show several advantages for biosensing applications.4,5
However, the availability of aptamer-ligands for small molecules
is still insuﬃcient.4 This is mainly due to the need for target
immobilization on a solid substrate during the SELEX, which
can be challenging for small drugs while at the same time
potentially decreasing the aptamer speciﬁcity.7
Aiming at circumventing this limitation, Nutiu and Li10
developed a target-immobilization free SELEX protocol suitable
for small molecules, later renamed capture-SELEX.11 Brieﬂy,
the oligonucleotide library is designed with a docking sequence
(of 15 nucleotides, nt) in between two randomized regions.
The docking region of the library is used to load the ssDNA
onto magnetic beads by hybridization with a complementary-
biotinylated binding oligo (BO). When the target molecule
binds to the recognizing ssDNA molecule, target-induced
conformational switching6 causes ssDNA elution from the bead
and therefore its selection. The original DNA-based capture-
SELEX strategy10 and its developments11,12 are based on
libraries with randomized region of only 30−50 nt, split in two
by a non variable region required for the capturing. Placing the
immobilization region between two randomized sequences
serves also to increase the chances that binding-induced
conformational changes will result in aptamer release. However,
longer randomized strings within the library sequence could
allow for greater structural or contextual complexity and
therefore could be preferable for targeting diﬀerent molecules.
Another DNA-based capture-SELEX has been developed for
metal ion targets (Zn2+) using a library with a continuous
randomized strand of 50 nt,14 but the library pool was
generated by a cumbersome combination of chemical synthesis,
PCR ampliﬁcation, in vitro transcription and reverse tran-
scription, and the whole protocols relies on ﬂuorescence
modiﬁcation of the library. A diﬀerent capture-SELEX protocol
uses a RNA-based library with a longer (60 nt) continuous
randomized strand,15 but brings along the common problems
of RNA-based probes like diﬃcult/expensive synthesis
(especially with modiﬁcations) and low resistance to biological
ﬂuids,16,17 therefore showing minor appeal for biosensing.
In the present work, we introduce a DNA based capture-
SELEX that combines the advantages of one single randomized
region of 60nt with the stability of the DNA backbone,
therefore merging high target versatility with stability of the
selected aptamers in complex matrices (e.g., blood serum). The
chosen target for the proof-of-concept SELEX is the amino-
glycoside tobramycin (molecular weight: 467 Da), for which
some RNA aptamers are available for comparison.15,18
Moreover, tobramycin concentration in patients’ blood needs
to be routinely controlled due to high patient variability in
tobramycin pharmacokinetics,19 therefore prompting the
development of a monitoring device addressed to this
application.
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Another long-established limitation of the SELEX is the
necessity of performing many cycles before identifying the
selected aptamers, thus making the selection of aptamers a
labor intensive and time-consuming process. Although some
works show SELEX protocol with signiﬁcantly reduced number
of cycles using CE-SELEX,8,20,21 high throughput sequencing
(HTS) based-SELEX22 or microﬂuidic/CHIP-based
SELEX,23−25 once again all the developed protocols are based
on target immobilization or are poorly adaptable to low
molecular weight targets. To investigate the progression of the
capture-SELEX more deeply and thus to understand if the
number of cycles can be drastically reduced, we coupled the
capture-SELEX for the ﬁrst time with a direct speciﬁcity
evaluation performed on a surface plasmon resonance platform
(SPR) and with HTS analysis of the selected cycle-libraries. In
the present work we demonstrate that DNA-based capture-
SELEX featuring a long and continuous randomized sequence
yields to aptamers showing high aﬃnity and that there is room
for dramatically reducing the number of cycles required to
select the best aptamer.
■ EXPERIMENTAL SECTION
Library Design and Oligonucleotides. The library was
designed similarly to the work on RNA of Morse,15 but on
DNA (Figure 1). The library consists of a 101 base long
oligonucleotide (Figure 1) with two constant regions of 21
nucleotides (nt) and 20 nt, on the 5′ and 3′, respectively, for
PCR primers annealing, and a central randomized region of 60
nt (corresponding to almost 1.33 × 1036 possible sequences).
12 nt of the 5′-end serve as docking sequence to load the
library onto the biotinylated superparamegnetic beads, while
the following 9nt before the randomized region served as
buﬀering region to be used in the library-loading optimization.
The library sequence is the following: 5′-GGAATGGATCCA-
CATCTACGA-(N)60-TTCACTGCAGACTTGACGAA-3′.
The primers used for ampliﬁcation are 5′-GATAATACG-
ACTCACTATAGGAATGGATCCACATCTACGA-3′ for the
forward (with 5′-thiol when the downstream application is SPR
instead of the SELEX), and 5′-phospho-AAGCTTCG-
TCAAGTCTGCAGTGAA-3′ for the reverse. The Binding
Oligonucleotide (BO) used to attach the library to the beads is
5′-TGGATCCATTCCATGCATCGATCGATC-3′-Biotin in
which the ﬁrst 12nt are annealing to the library. All
oligonucleotides were purchased from Sigma-Aldrich.
Library Preparation. The ﬁrst randomized ssDNA library
is ampliﬁed by PCR using 2.37 nmoles of ssDNA template
(about 1.43 × 1015 molecules out of 1.33 × 1036 possible
sequences), 2 mM MgCl2, 0.2 mM dNTPs, 1 μM of each
primer forward (5′-GATAATACGACTCACTATAGGAAT-
GGATCCACATCTACGA-3′) and reverse (5′-phopsho-
AAGCTTCGTCAAGTCTGCAGTGAA-3′), and 0.0125 U/
μL of Taq polymerase (Invitrogen and KAPA). Ampliﬁcation is
performed with the following cycle 2 min at 95 °C, 30 min at
95 °C to 30 min at 70 °C to 30 min at 72 °C for 25 times, 5
min at 72 °C, and it is veriﬁed by gel electrophoresis using
standard techniques (2% agarose gel). An aliquot of 4 mL of
the PCR product is then puriﬁed using the ChargeSwitch PCR
Clean-Up Kit (Invitrogen) following the manufacturer’s
Figure 1. DNA-based Capture-SELEX strategy. (A) Schematic of each cycle of the Capture-SELEX, which consists of four steps: (1) ssDNA library,
(2) binding of the ssDNA library to magnetic beads (B, separated via magnets, M) through a Binding Oligonucleotide (BO, in gray), (3) elution of
the ssDNA in response to binding of the target (T, yellow) and the consequent conformational change (the black ssDNA binds but does not change
conformation and it is therefore not eluted), (4) PCR ampliﬁcation of the eluted ssDNA using the designed primers (red and blue arrow). The
dsDNA ampliﬁed by PCR is then converted into the ssDNA library for the next cycle, therefore restarting at step 1. An aliquot of the eluted ssDNA
for each cycle has been used as template for the further analyses shown in the paper, as well as for the high-throughput sequencing library
preparation. (B) Structure and sequence of the ssDNA library (top) and of the biotinylated BO (bottom). The gray nucleotides show the annealing
part between the library and the BO.
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instructions (300 μL of bead slurry). The puriﬁed dsDNA
obtained is spectroscopically quantiﬁed using Nanodrop
(Thermo Scientiﬁc). dsDNA is converted in the ssDNA library
by taking advantage of the capability of the enzyme λ-
Exonuclease (Fermentas) of selectively digest the strand that
has a 5′ phosphorylation of a dsDNA. The reverse primer used
in the PCR is 5′ phosphorylated, thus allowing digestion of the
complementary strand. For dsDNA digestion roughly 100 μg
(1.6 nmol) of dsDNA are digested according to the
manufacturer instructions (150−210 U of enzyme) over a 4
h reaction. After enzyme heat-inactivation the ssDNA is
puriﬁed using the ChargeSwitch PCR Clean-Up Kit (Invi-
trogen) accordingly to the manufacturer’s protocol (300 μL of
bead slurry). The puriﬁed ssDNA obtained is spectroscopically
quantiﬁed using Nanodrop.
For the cycle-libraries (the pool at a given point in the
SELEX process) obtained after each cycle approximatively 80%
of the whole ssDNA recovered is used as PCR template with
the same recipe as above (ﬁnal volume 4 mL). The entire PCR
is subsequently puriﬁed and treated as described above to
obtain the ssDNA library for the next cycle (hereafter referred
to as cycle-library).
Selection Step. Roughly 24 μg (0.8 nmol) of ssDNA were
mixed with 4.8 μg (0.6 nmol) of biotinylated Binding
Oligonucleotide (BO, 5′-TGGATCCATTCCATGCATCGA-
TCGATC-3′-C6−Biotin) in 1× bind and wash buﬀer (B&W, 5
mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 1 M NaCl), and
incubated at 95 °C for 10 min, 60 °C for 5 min, and slowly
cooled down to 4 °C (ramp at about 0.05 °C/s) using a
thermomix (Eppendorf). This mix was then incubated with 360
μL of streptavidin coated beads (Dynabeads M-280, Life-
technology), previously washed 5 times in B&W buﬀer,
overnight at 4 °C in a rotating wheel. The supernatant was
then removed from the beads, and used to assess the binding
eﬃciency of the library to the beads. The beads were
subsequently washed twice with 10−15 beads volumes of 1×
BB (50 mM Tris pH 7.4, 500 mM NaCl). Bound ssDNA was
eluted by rotating for 1 h in 4 mL of BB containing tobramycin
(Sigma) at the concentration of 200 μM for the ﬁrst 4 cycles,
and at 20 μM for the others. Two identical aliquots of beads,
between 300 and 50 μL, were taken from the bead mix before
elution, and used for negative and control elution by incubating
them with 300 μL of either BB 1× (negative) or BB 1× with
the same concentration of tobramycin as the big elution
(positive). Eluted ssDNA was puriﬁed and concentrated using
the ChargeSwitch PCR Clean-Up Kit (Invitrogen) following
the manufacturer’s indications, using 100 μL of bead slurry (15
μL for each control elution) and eluting the ssDNA in the same
volume of the beads. While the main eluted ssDNA was
ampliﬁed by PCR as mentioned above, the control aliquots
were quantiﬁed by qPCR and semi-qPCR to assess the
speciﬁcity of the tobramycin elution.
SELEX Evaluation by SPR. Eluted ssDNA from cycle-
libraries of each even cycle of the SELEX was tested for aﬃnity
to the target tobramycin by performing a surface plasmon
resonance (SPR) assay. Brieﬂy, the puriﬁed ssDNA obtained
from the cycle was ampliﬁed by PCR with the primers forward
(th io -C6-5 ′ -GATAATACGACTCACTATAGGAAT-
GGATCCACATCTACGA-3′) and reverse (5′-phospho-
AAGCTTCGTCAAGTCTGCAGTGAA-3′) in parallel with
an aliquot of the initial library, and was then puriﬁed and
converted to ssDNA as described above. Solutions of 50 μL at
0.6 μM of each ssDNA were used for overnight functionaliza-
tion of SPR bare gold chip (Au-chip, BIAcore, GE Healthcare),
using the initial library for the reference ﬂow-cell, and the tested
cycle in the working ﬂow-cell. After passivation with 1 mM 6-
mercapto-hexanol for 30′, and several washes with TE 1X (10
mM Tris-HCl pH 7.4, 1 mM EDTA), the chip was used for
kinetic analysis in the SPR machine BIAcore X100 (BIAcore,
GE Healthcare). Running buﬀer and all the injections were
based on TE 1×, and several serial dilution solutions of
tobramycin (from 0.02 μM to 200 μM) were injected for 180 s
at 20 μL/min, followed by a dissociation time of 240 s at 20
μL/min and a regeneration injection of NaCl 1 M with SDS
0.2% (120 s at 5 μL/min with 120 s of stabilization). The
response was evaluated by ﬁtting the curves, obtained by
subtracting the signal from the reference ﬂow-cell from the
working ﬂow-cell signal, with the software Scrubber 2.0
(Biologic software).
Cycles-Library Sequencing and Sequence Analysis.
Aliquots of the even cycle-libraries from 2 to 12 were used as
PCR templates to generate the sequencing libraries. PCR
products were puriﬁed using the ChargeSwitch PCR Clean-Up
Kit (Invitrogen) following the manufacturer’s instructions using
13 μL of bead slurry, and yielding in more than 2.5 μg of
dsDNA per each cycle-library. Library were then bound to the
adaptors with one barcode per each cycle-library and sequenced
with an Illumina HiSeq 2500 (Illumina) by the sequencing
service of the University of Lausanne (Switzerland, unil.ch/
daﬂ/home.html), generating about 4 M reads per each cycle-
library. FastQ output ﬁles were reformatted to FASTA and low
quality sequences were ﬁltered out using a perl script (see
Supporting Information). Sequence clustering was performed
using a two steps strategy: Tallymer26 software were used to
recover the most frequent sequences per cluster (the full length
of 101 nt as K-mer size cutoﬀ); then for the best 50 sequences
per cluster a MegaBlast search has been performed in order to
allow a variability of 5% (∼3 nt considering only the variable
region) in the retrieved results. This allowed to obtain the
abundance of each cluster in every sequenced cycle-library, and
thus to determine its SELEX-driven enrichment (see
Supporting Information for further details on the analysis).
■ RESULTS
The SELEX Strategy. The selection strategy was designed
to obtain DNA molecules that bind the target and undergo a
major structural change causing their detachment from the
supporting beads (Figure 1a). Similar strategies, recently
referred to as capture-SELEX,11 have been previously
developed on DNA10 and RNA molecules.15. The DNA library
in this work bears an uninterrupted randomized region of 60
nucleotides ﬂanked by two ﬁxed regions. The 5′-constant
region is used for the primer annealing necessary for PCR
ampliﬁcation, and also as docking region for the capturing of
the DNA on the beads via the binding oligo (BO). A BO with
the docking sequence of 12 nt and a spacer of 14 nt was found
to have the maximal capturing eﬃciency with the minimal
docking region (data not shown).
Direct Evaluation of Aptamer Selection. Evaluating the
aptamer selection during the SELEX is crucial both to conﬁrm
that a selection is taking place,27 and to judge when to stop the
SELEX to retrieve the aptamer sequences. Many methods have
been proposed for this purpose in the SELEX protocols,
however they usually need target immobilization on a
support,21,28−32 or they infer selection indirectly by looking at
the decrease of complexity of the library.33 Avoiding target
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immobilization, capture-SELEX selection has so far been
indirectly evaluated by comparing the amount of eluted
ssDNA or RNA at each cycle with a blank control
elution.10−13,15,34 We therefore developed a direct protocol
that allows for the ﬁrst time in-stream direct quality control of
the selected cycle-libraries of ssDNA via SPR. Brieﬂy, an aliquot
of each selected ssDNA cycle-library (even cycles) and of the
initial library are used as template for a PCR with a thiolated 5′
primer and a phosphorylated 3′. PCR product can be thus
readily converted in a thiolated-ssDNA library that is amenable
for SPR-chip functionalization (see materials and methods).
SPR binding analyses were then performed using the original
library in the reference ﬂow-cell, the current cycle-library in the
working ﬂow-cell, and injecting tobramycin at concentrations
ranging from 0.02 to 200 μM (Figure 2A). The diﬀerential
signal shows a clear binding diﬀerence between initial and
selected cycle-libraries when using a late stage cycle-library (i.e.,
cycle number 12, Figure 2B). Kinetic analyses of the binding
curves obtained, performed at the saturation stage (see
materials and methods), allow to extract the maximum
response (Rmax) for tobramycin for the cycle-libraries of
each cycle (Figure 2C). From cycle number 8 on there is a clear
binding response, which increases until cycle number 12−14.
For the cycles earlier than number 8 it is not possible to detect
a binding stronger than the initial library, although this can be
hidden by the limit of detection of the SPR or by the unspeciﬁc
binding of tobramycin on both ﬂow-cells.
These results show that SPR analysis of the cycle-libraries
allows for direct target-binding evaluation of the capture-
SELEX, and that in our capture-SELEX on tobramycin a visible
enrichment starts at cycle 8 and goes toward saturation in cycle
12.
High-Throughput Sequencing of the Cycle-Libraries.
To assess how the population of sequences is evolving in the
cycle-libraries, we sequenced all the even cycle-libraries of our
capture-SELEX from cycle 2 to cycle 12. HTS analysis
(Illumina HiSeq), allows the simultaneous and quantitative
sequencing of a high number of individual ssDNA from each
SELEX cycle-library, hence giving full insights into the
evolution of the sequence populations.22,35,36 The six cycle-
libraries of cycles 2−4−6−8−10−12 have been sequenced in
parallel using 6 diﬀerent barcodes, with bidirectional reads of
101nt (over 124nt, Figure 1B), generating about 4 M reads per
cycle-library. After all the sequences with low quality and
sequences not starting or ending with one of the primers were
ﬁltered out, the sequences were clustered with the freely
available software Tallymer,26 setting the K-mer to the full
length (see materials and methods). Analyzing the number of
reads for the 50 most represented clusters per each cycle-library
shows that the complexity of the cycle-libraries decreases with
the progression of the SELEX (Figure 3A). Indeed, cycle-library
of cycle 2 only contains clusters with less than 50 sequences, of
which 80% are below 25 sequences, showing a high degree of
complexity. With the progression of the SELEX, the cycle-
libraries progressively decrease the fraction of clusters with only
25 sequences while increasing the more populated clusters.
Cycle-libraries of cycles 10 and 12 show a sharp increase of the
clusters with high enrichment (i.e., with more than 200, 225,
and 250 sequences). Comparing the size of each cluster
throughout the diﬀerent SELEX cycle-libraries clearly shows
that the vast majority of them get enriched after cycle 6,
although two clusters show an inconstant enrichment already in
cycle-libraries of cycle 4/6 (Figure 3B). Interestingly, when
comparing cluster frequencies of all cycles’ cycle-libraries
against cluster frequencies of the last cycle-library it emerges
that many of the mostly enriched clusters of cycle 12 are
already among the most abundant in the early cycles 2 and 4
(e.g., sequence ranked 2 in cycle 12 is also ranked 2 in cycle 2
and ranked 4 in cycles 4/8/10; Figure 3C). This indicates that
the enrichment of the best clusters of the last cycles starts
already at very early stages of the SELEX, although the number
of sequences per cluster is still low.
The ﬁrst HTS analysis performed on a capture-SELEX shows
that there is sequence convergence during the SELEX, and that
some clusters are clearly enriched from cycle 8, thus supporting
the increase of response to the target tobramycin seen by SPR.
Candidate Aptamer Evaluation. Following the HTS of
the last cycle (cycle 12), a list of the most populated 13 clusters
was created in order to ﬁnd the best aptamers. Aligning the
representative sequences of each of these 13 clusters shows that
there is no relevant homology between them (Figure 4A). Only
few short stretches of nucleotides have a signiﬁcant consensus.
In position 14−15 of the randomized part two nucleotides are
conserved in 9/13 clusters, while nucleotides 37 and 40 are
conserved in all the clusters.
In the 3′ end of the randomized part, there are two
conserved regions of 3 (47 to 49) and 4 nucleotides (56 to 59),
which are shared by more than 12/13 clusters. Although the
Figure 2. Direct analysis of aptamer selection. (A) Cycle-libraries of
each even cycle of the SELEX were analyzed for direct binding to the
target tobramycin via the SPR. The initial library (blue strings) was
immobilized on the reference ﬂow-cell (ﬂow-cell1) of the bare gold
SPR chip, while the working ﬂow-cell (ﬂow-cell2) was functionalized
with the cycle-library tested (red strings). Both ssDNA cycle-libraries
were attached via thiol-Au bond (spheres), and the whole chip was
passivated with 6-mercapto-1-hexanol (green) to reduce unspeciﬁc
binding. (B) Representative binding plot of the diﬀerential SPR signal
obtained subtracting ﬂow-cell1 to the signal of ﬂow-cell2 after
injections (gray box indicates injection time) of tobramycin solutions
at diﬀerent concentration (see legend on the right), RU: Response
Units. (C) Maximum response (Rmax) of tobramycin per each tested
cycle, calculated on the saturation point of each injection (see
materials and methods). RU: Response Units. Note that, despite the
low number of repetitions, the diﬀerence between cycle 12 and cycle
14 is not considered signiﬁcant (p = 0.19), while the diﬀerence
between cycle 10 and cycle 12 is (p = 0.06). Averages shown, error
bars represent standard deviations (n = 2 for all except cycle 12 for
which n = 3).
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homology of these parts might be high, their short span seems
to suggest that the clusters are diﬀerent between them, at least
in sequence. While identity higher than 70% is required to
merge two clusters,22 only less than 20% of the nucleotides in
the randomized part show an identity higher than 70% between
the 13 clusters. To further analyze possible structure similarities
between the clusters, the secondary structure of the
representative sequences were obtained by using the free-
energy minimization algorithm Mfold37 with salt correction at
room temperature. Between the various structure we could not
ﬁnd a shared substructure such as an hairpin, loop or bulge
(Supporting Information Figure 1) that is comparably long as
the reported binding sites for tobramycin.18,38 Indeed stem-
loops of 26−27 nt have been showed to wrap around
tobramycin, while we could ﬁnd in 12/13 candidates only a
stem sequence of 3 bp (5′-CCC-3′, or diﬀerent GC rich stems
of 3 bp) preceded and followed by diﬀerent structures/
sequences. Therefore, all the diﬀerent clusters were considered
as 13 new candidate DNA aptamers for tobramycin.
In order to evaluate the real speciﬁcity of the 13 new
candidate DNA aptamers for the tobramycin molecule, we
measured the binding via SPR. Similarly to the strategy used to
evaluate the aptamer selection during the SELEX, each
candidate was thiolated on the 5′ end and attached in ssDNA
form onto the bare gold surface of the working ﬂow-cell (ﬂow-
cell2, Figure 2A) of the SPR chip, while the reference ﬂow-cell
(ﬂow-cell1) was functionalized with a reference oligonucleo-
tide. The diﬀerential response clearly shows the binding of
tobramycin on the candidate aptamers (an example is shown in
Figure 4B) for diﬀerent concentrations of the drug. Binding
kinetic analysis of each candidate was then performed, and the
binding parameters were extracted (KD and Rmax, Table 1).
Since each independent SPR experiment was performed
identically (i.e., same oligonucleotide concentration for
functionalization), these data can be compared and used to
classify the candidate aptamers on their speciﬁcity for
tobramycin. Overall, the candidate aptamers tested show
aﬃnity constants in the submicromolar range, with a maximum
diﬀerence below 1 order of magnitude. Interestingly, the aﬃnity
does not perfectly copy the relative abundance, with 2 aptamers
of the lowest half of the table showing a KD similar to the ﬁrst
and second. Through sequence analysis and direct evaluation
by SPR we found 13 sequence-independent candidate
aptamers, of which 3 bind to tobramycin with a KD around
200 nM. The best aptamer found is CLSE1215, which shows an
aﬃnity constant for tobramycin slightly below 200 nM.
Aptamer selectivity toward for concomitantly administered
antibiotics (penicillin-like antibiotics like carbenicillin), and
similar aminoglycosides (kanamycin A) has been measured via
SPR with an identical protocol as described above. Carbenicillin
does not produce any visible signal even at 200 μM (data not
shown), while kanamycin gives a signal comparable to
tobramycin in the association at 200 μM (Supporting
Information Figure 2A). Interestingly, the dissociation of
kanamycin is quicker than tobramycin, thus reducing the
steady-state levels reached at lower concentrations. The KD of
the candidate aptamers for tobramycin is from 5 to 28 times
lower than for kanamycin (Supporting Information Figure 2B),
therefore showing a degree of selectivity between similar
molecules despite the lack of any negative selection step in the
capture-SELEX.
■ DISCUSSION
Aptamers are ideal ligands for small molecule detection in
biosensors.4−6 Despite thousands of papers on aptamers and an
ever increasing demand for drug-speciﬁc biosensors, the
availability of speciﬁc aptamers for small molecules is limited
because the need of target immobilization typical of many
SELEX protocols.7 In this work, we present a new capture-
SELEX method for developing DNA-based aptamers for small
drugs with high target-ﬂexibility because of the long and
continuous randomized region. Although the docking region is
placed outside the randomized sequence, therefore theoretically
reducing the conformational-change driven elution, the
capture-SELEX proposed succeeded to eﬃciently select binding
ssDNA aptamers.
The candidate aptamers found were evaluated for their
aﬃnity to the target tobramycin via direct immobilization onto
a SPR chip. The binding constants of the aptamers found are in
the high nanomolar range, with the best binders showing a KD
around 200 nM. Starting from a library with very similar
characteristic, aptamers for tobramycin developed by Morse on
Figure 3. Sequence analysis of the cycle-libraries shows clusters
convergence and enrichment. (A) Fraction of the most abundant 50
clusters with the speciﬁed number of sequences (see legend on the
right) in each the SELEX-cycles. Note that with the progression of the
SELEX the number of clusters with high number of sequences steadily
increases. (B) Abundance (number of sequences) per each cluster in
each SELEX cycle. Each line represents a single cluster. Clusters are
then ordered according to their abundance in the cycle 12. Due to
space restriction the cluster names are not shown in the ﬁgure legend.
(C) Ranking based on the abundance of the 10 most populated
clusters of SELEX cycle 12 in the libraries from SELEX cycle 2 to cycle
10 (see legend on the right). Note that the most abundant 5 clusters of
SELEX cycle 12 and clusters 8 and 11 are also among the biggest
clusters in almost all the earlier cycle-libraries. Gray shade shows the
colinear enrichment area.
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RNA15 were reported with orders of magnitude higher binding
constant of 16 and 500 μM, although this was measured by
means of diﬀerent techniques (ﬂuorescence quenching). With
the aim to investigate the mechanism of action of the antibiotic,
shorter RNA-based aptamers speciﬁc for tobramycin were
selected by Wang and Rando some 20 years ago18 with KD
around 10 nM. Once again, the aﬃnity was tested with a
diﬀerent assay (ﬂuorescence-quenching competition). How-
ever, one of the same RNA-aptamers was later tested on SPR
by Verhelst and co-workers,39 showing the best KD around 0.2
μM which has been conﬁrmed in our lab (data not shown).
Furthermore, in another recent paper short DNA-based
aptamers were selected for kanamycin, but were also tested
for tobramycin binding.40 In ﬂuorescence intensity analysis
assays both kanamycin and tobramycin show dissociation
constant around 0.1 μM, hence similar to the KD of the
aptamers selected in this work. Overall, comparing the aﬃnities
of our aptamers with the others available clearly indicates that
RNA-based aptamers are not more avid for tobramycin than
DNA-aptamers, and that the protocol developed in this work is
able to select aptamers with similar low KD than capture and
“classic” SELEX.
SELEX progression has to be evaluated at each cycle, and it is
usually performed by quantifying the radioactive/ﬂuorescent
oligonucleotides eluted (depending on the SELEX type this
would be used to infer the discarded or selected oligonucleo-
tides),27 or as recently proposed by evaluating the library
complexity through melting curve analysis.33 Although
important, the above-mentioned methods extrapolate the
selection for target-speciﬁc oligonucleotides from indirect
events like library complexity or increased elution, which
could be severely impacted by unforeseen biases common in
SELEX protocols. The presented direct evaluation of the
SELEX progression via SPR-based measurement of the target-
Figure 4. Candidate aptamers evaluation. (A) Sequence alignment of the most enriched 13 aptamers of cycle-library cycle 12. Light blue shading
represents identity in 40−60% of the sequences, medium blue in 60−80% and dark blue in 80−100%. (B) Representative binding plot of the SPR
analysis carried out on each candidate aptamer to evaluate the binding kinetic parameters with the target tobramycin. The plot shown is relative to
the candidate CLSE1201 and it has been obtained using the whole sequence including the primer regions. Injection time is highlighted in gray in the
x-axis.
Table 1. Validation of the Candidate Aptamers for
Tobramycin Aﬃnity and Maximum Response Calculated
from the SPR Experiments (on Sequences Including the
Primers)
candidate aptamer no. of sequences in cycle 12 KD (μM) Rmax (RU
a)
CLSE1201b 1866 0.23 57.0
CLSE1203 1441 0.34 69.1
CLSE1205 676 0.65 54.0
CLSE1208 602 0.43 52.3
CLSE1206 590 0.66 65.9
CLSE1231 443 0.49 71.5
CLSE1215 375 0.30 67.1
CLSE1214 398 0.43 74.3
CLSE1220 344 0.26 31.7
CLSE1213 354 0.44 41.2
CLSE803 294 0.41 46.6
CLSE1216 302 0.54 60.2
CLSE1219 301 0.15 62.1
aResponse units (arbitrary units from the SPR plots). bShort version
without primers show a KD of 0.52 μM
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aﬃnity of the cycle-libraries overcomes this problem. We show
that starting from cycle 8 the selected cycle-library shows a
detectable, and since then increasing, binding of the target
tobramycin, which is independent from any bias that might
arise from other factors diﬀerent from the target drug. Notably,
the binding response peaks around cycle 12, therefore allowing
to consciously stopping the SELEX to sequence the cycle-
library (or to change parameters like stringency). This can play
an important role in the quest of reducing the required number
of cycles necessary to identify the target-speciﬁc aptamers.
However, we do only see binding from cycle 8, which is clearly
not a massive reduction of cycles number from 12. This could
be due to the small molecular mass of tobramycin, which in a
label-free mass-dependent assay like the SPR can hinder the
detection of minor bindings. One alternative is to change for a
signal-oﬀ SPR assay that exploits the oligonucleotide detach-
ment (higher mass than tobramycin) from the surface used
during the SELEX itself. A signal-oﬀ SPR assay has been tested
for the similar antibiotics kanamycin by others,41 but it seems
to produce responses similar to our direct SPR assay for
tobramycin. Another possibility is to improve the signal-to-
noise ratio of the SPR by using more sensitive machines (like
the BIAcore T100, GE healthcare, (their Web site), or by
improving chip surface coverage.
On the other hand high-throughput sequencing has been
reported to have the sensitivity required to drastically reduce
the number of cycles in “classic” SELEX.22,42 Performing HTS
followed by rigorous sequence analysis on the presented
capture-SELEX shows for the ﬁrst time that the direct target-
binding response of the cycle-libraries from cycle 8 is supported
by an abrupt convergence of the libraries toward speciﬁc
aptamers. More importantly, HTS analysis reveals that the most
enriched aptamers of the last cycle-library are indeed already
the most enriched in the early cycles, going down to cycle
number 2 and hence showing potential to radically reduce the
number of SELEX cycles required. However, the abundance
ranking of cycle-library cycle 2 is only based on tens of
sequences per cluster, and it is therefore prone to misleading
ranking due to small biases. Nevertheless, with the continuous
decrease of HTS costs and increase of their availability
(reducing the waiting time for service-based HTS) it is not
imprudent to foresee its use in capture-SELEX, even if only as
SELEX evaluation tool, provided that the sequence analysis is
thoroughly coupled with direct target-binding assays.
Tobramycin served in this work as proof-of-concept small
drug target, but its frequent quantiﬁcation in patients’ blood,
necessary to personalize the treatment,19 spurs on the
development of speciﬁc point-of-care biosensors.43 Currently
tobramycin in serum needs to be precisely measured in a
concentrations range between 1 μM and 80 μM (Prof. T.
Buclin and Prof. L. Decosterd, personal communication). The
aptamers selected in the present work show a clear signal for
tobramycin in buﬀer starting from 50 nM, while capture-
SELEX obtained RNA-aptamers by Morse only sees
tobramycin from around 20 μM.15 Importantly, our aptamers
do not show any binding with coadministered antibiotics from
the penicillin group (e.g., carbenicillin, data not shown), while
the exhibit more than 20-fold higher KD with the similar
aminoglycoside kanamycin. This leaves room for cushioning
possibly required serum dilutions and hopefully for loss of
signal due to the much stronger matrix eﬀect of human serum.
■ CONCLUSIONS
We present here a new DNA-based capture-SELEX protocol
for targeting small drugs (target-derivatization free) coupled
with SPR in-stream evaluation and HTS analysis, which is
ﬂexible and bears potential for strongly reducing the number of
required cycles. Using this protocol for other drugs will assess
its true ﬂexibility and speed of aptamer selection. Moreover,
binding assays show that the selected aptamers are comparable
with the available ones and that they might bear the capacity to
detect tobramycin in label-free surface detection in the relevant
blood concentration range.
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